Status:

RECRUITING

3DPCT Combined With CT Guided RISI in the Treatment of Thoracic Malignant Tumors

Lead Sponsor:

Peking University Third Hospital

Conditions:

Radioactive Iodine-125 Brachytherapy

Thoracic Cancer

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The main technical difficulties in radioactive iodine-125 seed implantation (RISI) lie in the complexity of operation and the control of operation quality. The current data shows that under the combin...

Eligibility Criteria

Inclusion

  • Pathological diagnosis of malignant tumor of chest, lesion diameter less than 7 cm.
  • There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by early treatment.
  • No bleeding tendency, anticoagulant therapy and / or antiplatelet coagulation drugs should be stopped for at least 1 week before treatment.
  • No serious or uncontrolled underlying diseases (such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction) are found.
  • There is a suitable puncture path, and the therapeutic dose is expected to be achieved.
  • KPS \> 70, expected to tolerate puncture / seed implantation, and expected survival time greater than 3 months.

Exclusion

  • Severe impairment of lung function (such as FEV1 \< 40% predicted value, FVC \< 50% predicted value, DLCO \< 40% predicted value).
  • High risk of skin invasion and ulceration at the puncture site before treatment.
  • There is a large range of liquefaction and necrosis in the lesion, and the expected seed distribution would be poor.
  • Pregnant women, lactating women and mentally ill patients.
  • The patient with poor compliance and unable to complete the treatment.
  • Other conditions of the researchers who think it is not suitable to participate in this clinical trial.

Key Trial Info

Start Date :

May 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 30 2026

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT05351268

Start Date

May 1 2022

End Date

April 30 2026

Last Update

December 20 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Peking University Third Hospital

Beijing, Beijing Municipality, China, 100191